Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

Investor Alert: Holzer Holzer & Fistel, LLC Advises Investors of Upcoming Deadlines in Shareholder Litigation Involving magicJack VocalTec LTD., Tellabs, Inc. and Keryx Biopharmaceuticals


Print article Print article
© Marketwire 2013
2013-02-13 17:44:01 -

ATLANTA, GA -- (Marketwire) -- 02/13/13 -- Holzer Holzer & Fistel LLC reminds investors of upcoming deadlines for applications to serve as lead plaintiff in securities class action lawsuits against magicJack VocalTec LTD (CALL), Tellabs, Inc. (TLAB) and Keryx Biopharmaceuticals, Inc. (KERX).



Investors that suffered significant losses investing in any of these companies during the specified times who are interested in potentially serving as lead plaintiff in the respective class actions are encouraged to contact Michael I. Fistel, Jr., Esq. ( mfistel@holzerlaw.com : mailto:mfistel@holzerlaw.com ) or Marshall P. Dees, Esq. ( mdees@holzerlaw.com : mailto:mdees@holzerlaw.com ) by email or via toll-free telephone at (888) 508-6832 to discuss their legal rights.





magicJack VocalTec LTD



A class action lawsuit has been filed on behalf of investors who purchased magicJack (NASDAQ: CALL) securities between February 28, 2012 and January 8, 2013. The lawsuit alleges the company violated the federal securities laws by, among other things, allegedly overstating the Company's earnings, revenue and cash flows during that time.



The deadline to seek appointment as lead plaintiff in this lawsuit, which is pending in the United States District Court for the Southern District of New York, is March 19, 2013. More information about the lawsuit and the firm are available at www.holzerlaw.com : ctt.marketwire.com/?release=985507&id=2612494&type=1& .. .



Tellabs, Inc.



A class action lawsuit has been filed on behalf of investors who purchased Tellabs Inc. (NASDAQ: TLAB) common stock between October 26, 2010 and April 26, 2011, inclusive, alleging the company violated the federal securities laws by making false and misleading statements relating to, among other things, demand for its products and earnings guidance during that time.



The deadline to seek appointment as lead plaintiff in this lawsuit, which is pending in the United States District Court for the Northern District of Illinois, is March 25, 2013. More information about the lawsuit and the firm are available at www.holzerlaw.com : ctt.marketwire.com/?release=985507&id=2612497&type=1& .. .



Keryx Biopharmaceuticals, Inc.



A class action lawsuit has been filed on behalf of investors who purchased Keryx (NASDAQ: KERX) common stock between June 1, 2009 and April 1, 2012. According to the complaint, the company is alleged to have violated the federal securities laws by issuing false and misleading statements regarding its phase 3 clinical trial of perifosine.



The deadline to seek appointment as lead plaintiff in this lawsuit, which is pending in the United States District Court for the Southern District of New York, is April 2, 2013. More information about the lawsuit and the firm are available at www.holzerlaw.com : ctt.marketwire.com/?release=985507&id=2612500&type=1& .. .



About The Firm



Holzer Holzer & Fistel, LLC dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com : ctt.marketwire.com/?release=985507&id=2612503&type=1& .. and upon request from the firm. Holzer Holzer & Fistel, LLC has paid for the dissemination of this promotional communication, and Michael I. Fistel, Jr. is the attorney responsible for its content.



Press Information:




Contact Person:


Disclaimer: (c) 2014 Market Wire. All of the press releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Market Wire's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser